225 related articles for article (PubMed ID: 32497550)
1. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
Vagiannis D; Yu Z; Novotna E; Morell A; Hofman J
Biochem Pharmacol; 2020 Aug; 178():114061. PubMed ID: 32497550
[TBL] [Abstract][Full Text] [Related]
2. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract][Full Text] [Related]
3. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Hofman J; Sorf A; Vagiannis D; Sucha S; Kammerer S; Küpper JH; Chen S; Guo L; Ceckova M; Staud F
Mol Pharm; 2019 Nov; 16(11):4436-4450. PubMed ID: 31633365
[TBL] [Abstract][Full Text] [Related]
4. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.
Vagiannis D; Zhang Y; Budagaga Y; Novotna E; Skarka A; Kammerer S; Küpper JH; Hofman J
Toxicol Appl Pharmacol; 2022 Jan; 434():115823. PubMed ID: 34896433
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
7. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D; Staud F; Ceckova M
Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
[TBL] [Abstract][Full Text] [Related]
8. Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme.
Vagiannis D; Novotna E; Skarka A; Kammerer S; Küpper JH; Chen S; Guo L; Staud F; Hofman J
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32231067
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
10. Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo.
Vagiannis D; Budagaga Y; Morell A; Zhang Y; Novotná E; Skarka A; Kammerer S; Küpper JH; Hanke I; Rozkoš T; Hofman J
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769363
[TBL] [Abstract][Full Text] [Related]
11. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
12. Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo.
Zhang Y; Vagiannis D; Budagaga Y; Sabet Z; Hanke I; Rozkoš T; Hofman J
Biochem Pharmacol; 2022 May; 199():115009. PubMed ID: 35314165
[TBL] [Abstract][Full Text] [Related]
13. Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.
Hofman J; Vagiannis D; Chen S; Guo L
Chem Biol Interact; 2021 May; 340():109448. PubMed ID: 33775687
[TBL] [Abstract][Full Text] [Related]
14. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
15. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
Wu ZX; Teng QX; Cai CY; Wang JQ; Lei ZN; Yang Y; Fan YF; Zhang JY; Li J; Chen ZS
Biochem Pharmacol; 2019 Aug; 166():120-127. PubMed ID: 31078601
[TBL] [Abstract][Full Text] [Related]
16. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
17. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
18. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells.
Liu DL; Li YJ; Yao N; Xu J; Chen ZS; Yiu A; Zhang CX; Ye WC; Zhang DM
Eur J Pharmacol; 2014 Jun; 733():34-44. PubMed ID: 24704556
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.
Sorf A; Vagiannis D; Ahmed F; Hofman J; Ceckova M
Toxicol Appl Pharmacol; 2022 Jan; 434():115797. PubMed ID: 34780725
[TBL] [Abstract][Full Text] [Related]
20. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
